1st Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Period 1st Quarter 2013 Filed Apr 20, 2013 Signed by Francesca Fierro O'Reilly, Vice President, Government Relations

Official filing
Firm
AMERICAN CLINICAL LABORATORY ASSN
Client
AMERICAN CLINICAL LABORATORY ASSN
Income
—
Expenses
$190,738
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JENNIFER BULLARD MADSEN —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN New —

Contacted: Congressional Budget Office (CBO); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; President of the U.S.; Office of Management & Budget (OMB); SENATE; Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JENNIFER BULLARD MADSEN —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); President of the U.S.

Budget/Appropriations BUD

Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JENNIFER BULLARD MADSEN —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN New —

Contacted: Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); President of the U.S.; Medicare Payment Advisory Commission (MedPAC)

Medical/Disease Research/Clinical Labs MED

Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JENNIFER BULLARD MADSEN —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN New —

Contacted: President of the U.S.; SENATE; Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.